AZD-1705 is under clinical development by AstraZeneca and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I drugs for Dyslipidemia have a 68% phase transition success rate (PTSR) ...
Purpose: This study aims to assess the causal relationship between Obstructive Sleep Apnea (OSA), dyslipidemia, and osteoporosis using Mendelian Randomization (MR) techniques. Conclusion: The study ...
Four classes of lipid-lowering drugs are available: the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the "statins"), the fibrates (gemfibrozil, clofibrate, and fenofibrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback